These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37722600)

  • 1. Strategies for Tailored Antiplatelet Therapy after Percutaneous Coronary Intervention: Unraveling Complexities, Embracing Nuances.
    Landolina D; Ammirabile N; Capodanno D
    Thromb Haemost; 2024 May; 124(5):497-499. PubMed ID: 37722600
    [No Abstract]   [Full Text] [Related]  

  • 2. Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention.
    Galli M; Ortega-Paz L; Franchi F; Rollini F; Angiolillo DJ
    Pharmacogenomics; 2022 Aug; 23(13):723-737. PubMed ID: 35938534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet function testing and tailored antiplatelet therapy.
    Janssen PW; ten Berg JM
    J Cardiovasc Transl Res; 2013 Jun; 6(3):316-28. PubMed ID: 23543615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary intervention: A network meta-analysis of randomized clinical trials.
    Kheiri B; Abdalla A; Osman M; Barbarawi M; Zayed Y; Haykal T; Chahine A; Bachuwa G; Hassan M; Bhatt DL
    Catheter Cardiovasc Interv; 2019 Aug; 94(2):181-186. PubMed ID: 30628754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use new antiplatelet therapies consistently in clinical practice.
    Aalbers J
    Cardiovasc J Afr; 2013 Apr; 24(3):100. PubMed ID: 23736138
    [No Abstract]   [Full Text] [Related]  

  • 6. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
    Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
    Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention.
    Bagai A; Bhatt DL; Eikelboom JW; Mancini GB; Cohen EA; Vijayaraghavan R; Cheema AN; Udell JA; Niznick J; Tanguay JF; Verma S; Mehta SR
    Circulation; 2016 May; 133(21):2094-8. PubMed ID: 27217435
    [No Abstract]   [Full Text] [Related]  

  • 8. The Past, Present, and Future of Dual-Antiplatelet Therapy Duration in Percutaneous Coronary Intervention.
    Abbott JD
    Ann Intern Med; 2017 Jul; 167(1):57-58. PubMed ID: 28605778
    [No Abstract]   [Full Text] [Related]  

  • 9. Still a Long Way to the Precision Medicine of Antiplatelet Strategy After Percutaneous Coronary Intervention.
    Jeong YH; Obayashi Y; Song H; Kimura T
    Circ Cardiovasc Interv; 2022 Aug; 15(8):e012261. PubMed ID: 35899617
    [No Abstract]   [Full Text] [Related]  

  • 10. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y
    Sibbing D; Aradi D; Alexopoulos D; Ten Berg J; Bhatt DL; Bonello L; Collet JP; Cuisset T; Franchi F; Gross L; Gurbel P; Jeong YH; Mehran R; Moliterno DJ; Neumann FJ; Pereira NL; Price MJ; Sabatine MS; So DYF; Stone GW; Storey RF; Tantry U; Trenk D; Valgimigli M; Waksman R; Angiolillo DJ
    JACC Cardiovasc Interv; 2019 Aug; 12(16):1521-1537. PubMed ID: 31202949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
    Zhou Y; Wang Y; Wu Y; Huang C; Yan H; Zhu W; Xu W; Zhang L; Zhu J
    BMC Cardiovasc Disord; 2017 Jun; 17(1):157. PubMed ID: 28619104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH;
    Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perceived or Calculated Bleeding Risk and Their Relation With Dual Antiplatelet Therapy Duration in Patients Undergoing Percutaneous Coronary Intervention.
    Ferlini M; Rossini R; Musumeci G; Grieco N; Demarchi A; Trabattoni D; Zavalloni Parenti D; Pierini S; Castiglioni B; Somaschini A; Cornara S; Lettieri C; Oltrona Visconti L
    Circ Cardiovasc Interv; 2019 Jun; 12(6):e007949. PubMed ID: 31142150
    [No Abstract]   [Full Text] [Related]  

  • 14. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial.
    Zheng YY; Wu TT; Yang Y; Hou XG; Gao Y; Chen Y; Yang YN; Li XM; Ma X; Ma YT; Xie X
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):211-221. PubMed ID: 31603191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
    Laine M; Camoin-Jau L; Bessereau J; Sébastien A; Paganelli F; Bonello L
    Curr Pharm Des; 2012; 18(33):5392-401. PubMed ID: 22724420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet De-Escalation Strategies in Patients Undergoing Percutaneous Coronary Intervention.
    Spirito A; Krishnan SL; Capodanno D; Angiolillo DJ; Mehran R
    Circ Cardiovasc Interv; 2024 Apr; 17(4):e013263. PubMed ID: 38626078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of duration of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention.
    Khan SU; Riaz IB; Rahman H; Lone AN; Raza M; Khan MS; Riaz A; Kaluski E
    Eur J Prev Cardiol; 2019 Mar; 26(4):429-432. PubMed ID: 30152256
    [No Abstract]   [Full Text] [Related]  

  • 18. Personalized antiplatelet therapy: the wrong approach?
    Collet JP; Montalescot G
    Arch Cardiovasc Dis; 2013 Oct; 106(10):481-6. PubMed ID: 24080323
    [No Abstract]   [Full Text] [Related]  

  • 19. Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
    Brener SJ; Kirtane AJ; Rinaldi MJ; Stuckey TD; Witzenbichler B; Weisz G; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Brodie BR; Mehran R; McAndrew T; Stone GW
    Circ Cardiovasc Interv; 2018 Oct; 11(10):e006853. PubMed ID: 30354629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal antiplatelet therapy in patients at high bleeding risk undergoing complex percutaneous coronary intervention.
    Ortega-Paz L; Angiolillo DJ
    Eur Heart J; 2022 Sep; 43(33):3115-3117. PubMed ID: 35861271
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.